Prevention of Preterm Birth With a Pessary in Twin Gestations

Overview

Preterm birth (PTB) is a major health problem and contributes to more than 50% of the overall perinatal mortality. Twins are at increased risk for PTB. The number of twins births has risen substantially due to the increased use of assisted reproductive technology. The rate of twin births in the United States rose from 18.9 to 32.2 per 100 live births between 1980 and 2004. The increased rate of PTB in twins is associated with increased morbidity and mortality rates. Almost one in four very low birth-weight infants (below 1500 g) born in the United States are twins, as are one in six infants who die in the first month of life. Cervical shortening is a risk factor for PTB. Transvaginal ultrasound measurement of cervical length is a reliable screening test for prediction of PTB. There is currently no effective treatment to decrease the incidence of PTB in women with twin gestations, but there is some evidence that the use of a cervical pessary in women with a short cervix has promise. If effective this approach would be particularly appealing because of the wide availability of pessaries, ease of use, and low cost. Unfortunately, existing studies are inadequate to confirm effectiveness; a well designed, properly powered, prospective randomized trial is warranted prior to widespread implementation in clinical practice. We propose such a trial to study the effectiveness of the pessary in decreasing the incidence of PTB in an inner city Philadelphia population.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2016

Interventions

  • Device: Bioteque cup pessary

Arms, Groups and Cohorts

  • Experimental: Pessary
    • Use of the Bioteque cup pessary. Pessary will be placed between 18 and 27 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
  • No Intervention: No pessary
    • No pessary will be used. Subjects will receive standard obstetrical management

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With Preterm Delivery
    • Time Frame: Less than 34 weeks gestation

Secondary Measures

  • Average Birth Weight of Babies in Each Group
    • Time Frame: Time of delivery
    • The birth weight of babies is the pessary group and no pessary group were recorded and analyzed for comparison.
  • Spontaneous Preterm Birth Rates
    • Time Frame: Less than 37 weeks gestation
  • Number of Participants That Experienced Neonatal Death
    • Time Frame: Between birth and 28 days of age
    • Number of participants that experienced neonatal deaths that occurred in each group following birth was recorded and analyzed.
  • Number of Subjects Experiencing Chorioamnionitis
    • Time Frame: Time of delivery
    • Chorioamnionitis was recorded and analyzed for participants in each group.

Participating in This Clinical Trial

Inclusion Criteria

  • 18-50 years of age – Twin pregnancy (limits the participants to female gender) – Short cervical length (less than or equal to 30 mm) on second trimester ultrasound at 18-27 6/7 weeks gestation Exclusion Criteria:

  • Singleton or higher order than twins multiple gestation – Monoamniotic twins – Twin twin transfusion syndrome – Ruptured membranes – Lethal fetal structural anomaly – Fetal chromosomal abnormality – Cerclage in place (or planned placement) – Vaginal bleeding – Suspicion of chorioamnionitis – Ballooning of membranes outside the cervix into the vagina – Painful regular uterine contractions – Labor – Placenta previa

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Pennsylvania
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Lorraine Dugoff, MD, Principal Investigator, University of Pennsylvania
    • Vincenzo Berghella, Principal Investigator, Thomas Jefferson University
    • Jack Ludmir, Principal Investigator, University of Pennsylvania

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.